ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
105,554.84
-0.58%
S&P 500
6,049.24
0.88%
Dow Jones
44,025.81
1.24%
US Dollar vs Yen
155.936
0.10%
Brent Oil
78.63
-0.15%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ

  6. Ocugen Inc (OCGN) 銘柄情報

Ocugen Inc

Ocugen Inc (OCGN)

NASDAQ
0.7497
0.0397
(5.59%)
終了 1月22日 6:00AM
15分遅延
0.7499
0.0002
(0.03%)
取引時間後: 9:59AM
15分遅延

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

主要統計と詳細

通貨
0.7499
買値
0.742
売値
0.75
出来高
5,688,404
0.72 日の範囲 0.7694
0.495 52 週間の範囲 2.105
時価総額
218.461M
前日終値
0.71
始値
0.735
時刻
4922
@
0.7499
(formt)
最終取引時間
財務取引量
US$ 4,268,921
VWAP
0.75046
平均取引量 (3 か月)
4,820,546
発行済株式数
291,320,280
配当利回り
-
PER
-3.46
1 株当たり利益 (EPS)
-0.22
歳入
6.04M
純利益
-63.08M

Ocugen Inc について

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal... Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. 詳細を表示

セクター
Biological Pds,ex Diagnstics
業界
Ortho,prosth,surg Appl,suply
ウェブサイト
ocugen.com
本社
Wilmington, Delaware, USA
設立
2020
Ocugen Inc is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker OCGN. The last closing price for Ocugen was US$0.71. Over the last year, Ocugen shares have traded in a share price range of US$ 0.495 to US$ 2.105.

Ocugen currently has 291,320,280 shares in issue. The market capitalisation of Ocugen is US$206.84 million. Ocugen has a price to earnings ratio (PE ratio) of -3.46.

OCGN 最新ニュース

その他のニュース

Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema

MALVERN, Pa., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...

2025年1月16日
GlobeNewswire Inc.

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects...

2025年1月13日
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

2025年1月7日
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

2025年1月7日
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

2025年1月7日
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

2025年1月7日
Edgar (US Regulatory)

Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

OCU410 has a very favorable safety and tolerability profileNo serious adverse events related to the study drug have been reported, such as exudation, infectious endophthalmitis, intraocular...

2024年12月19日
GlobeNewswire Inc.

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit

MALVERN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...

2024年12月11日
GlobeNewswire Inc.

Form 8-K - Current report

2024年12月3日
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

2024年12月3日
Edgar (US Regulatory)
期間 †前日比前日比 %始値高値安値平均出来高VWAP
1-0.0031-0.4116865869850.7530.7710.69548772430.72196699CS
4-0.0097-1.276987888360.759610.6950676170.80931868CS
12-0.2801-27.19417475731.031.130.6948205460.8667436CS
26-0.9201-55.09580838321.671.720.6943164201.02825201CS
520.229944.21153846150.522.1050.49558715711.27447327CS
156-2.7101-78.32658959543.464.530.34559381121.6297363CS
2600.02994.152777777780.7218.770.17165887275.3847041CS

OCGN - Frequently Asked Questions (FAQ)

What is the current Ocugen share price?
The current share price of Ocugen is US$ 0.7499
How many Ocugen shares are in issue?
Ocugen has 291,320,280 shares in issue
What is the market cap of Ocugen?
The market capitalisation of Ocugen is USD 206.84M
What is the 1 year trading range for Ocugen share price?
Ocugen has traded in the range of US$ 0.495 to US$ 2.105 during the past year
What is the PE ratio of Ocugen?
The price to earnings ratio of Ocugen is -3.46
What is the cash to sales ratio of Ocugen?
The cash to sales ratio of Ocugen is 36.23
What is the reporting currency for Ocugen?
Ocugen reports financial results in USD
What is the latest annual turnover for Ocugen?
The latest annual turnover of Ocugen is USD 6.04M
What is the latest annual profit for Ocugen?
The latest annual profit of Ocugen is USD -63.08M
What is the registered address of Ocugen?
The registered address for Ocugen is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Ocugen website address?
The website address for Ocugen is ocugen.com
Which industry sector does Ocugen operate in?
Ocugen operates in the ORTHO,PROSTH,SURG APPL,SUPLY sector

ムーバー

すべて表示
  • 出来高
  • 値上がり率
  • 値下がり率
銘柄コード株価出来高
ASSTAsset Entities Inc
US$ 0.8998
(93.71%)
263.47M
DWTXDogwood Therapeutics Inc
US$ 3.18
(70.05%)
24.31M
USEGUS Energy Corp
US$ 3.74
(61.21%)
107.79M
DOGZDogness International Corporation
US$ 27.62
(52.60%)
1.95M
MYNAMynaric AG
US$ 0.6697
(50.83%)
3.72M
GOEVCanoo Inc
US$ 0.3748
(-72.24%)
41.38M
SHOTWSafety Shot Inc
US$ 0.1094
(-47.40%)
18.06k
ORKTOrangeKloud Technology Inc
US$ 0.7068
(-36.89%)
7.48M
HEPAHepion Pharmaceuticals Inc
US$ 0.3219
(-31.36%)
1.66M
WNWMeiwu Technology Company Ltd
US$ 0.2681
(-27.05%)
11.02M
GCTKGlucoTrack Inc
US$ 0.1226
(44.41%)
613.28M
CRKNCrown Electrokinetics Corporation
US$ 0.1121
(-10.32%)
392.52M
ASSTAsset Entities Inc
US$ 0.8998
(93.71%)
262.98M
RIMEAlgorhythm Holdings Inc
US$ 0.034599
(-16.83%)
230.08M
RGTIRigetti Computing Inc
US$ 13.97
(42.12%)
226.81M

OCGN Discussion

投稿を表示

最近閲覧した銘柄

NASDAQ
OCGN
Ocugen
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有